| scholarly article | Q13442814 |
| P50 | author | Souparno Bhattacharya | Q86128289 |
| P2093 | author name string | Aroumougame Asaithamby | |
| P2860 | cites work | Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target | Q37786126 |
| Strategies to improve radiotherapy with targeted drugs | Q37856721 | ||
| Anticancer therapy with checkpoint inhibitors: what, where and when? | Q37860458 | ||
| Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit | Q37871600 | ||
| CDC25 phosphatase inhibitors: an update | Q37954441 | ||
| Charged particles in radiotherapy: a 5-year update of a systematic review | Q37983317 | ||
| An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. | Q37992341 | ||
| Progress in radiotherapy for pediatric sarcomas | Q38005355 | ||
| Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. | Q38019607 | ||
| Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. | Q38021464 | ||
| Radiation-induced brain injury: A review | Q38029608 | ||
| PARP inhibitors in cancer therapy: an update. | Q38078993 | ||
| Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review | Q38099763 | ||
| Biological consequences of radiation-induced DNA damage: relevance to radiotherapy | Q38121236 | ||
| Effects of ionizing radiation on mitochondria | Q38124680 | ||
| Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms. | Q38268221 | ||
| DNA double-strand break repair inhibitors as cancer therapeutics | Q38314520 | ||
| Integrating genetic approaches into the discovery of anticancer drugs | Q38555487 | ||
| Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review | Q38648782 | ||
| Ionizing radiation and heart risks. | Q38724349 | ||
| Combining carbon ion irradiation and non-homologous end-joining repair inhibitor NU7026 efficiently kills cancer cells | Q38820654 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| The DNA-damage response in human biology and disease | Q24606586 | ||
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells | Q24644828 | ||
| Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University | Q26744799 | ||
| Emerging Treatment Paradigms in Radiation Oncology | Q26853461 | ||
| Overview of base excision repair biochemistry | Q27021659 | ||
| Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers | Q27022514 | ||
| RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA | Q27314893 | ||
| Structural basis for Chk1 inhibition by UCN-01 | Q27639676 | ||
| Discovery of a Potent Inhibitor of Replication Protein A Protein–Protein Interactions Using a Fragment-Linking Approach | Q27680422 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Targeting the DNA Damage Response in Cancer | Q28082178 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Up‐regulation of DNA‐dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma | Q28209405 | ||
| PARP inhibitors stumble in breast cancer | Q28237027 | ||
| A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia | Q28249342 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| Exploring the role of cancer stem cells in radioresistance | Q28282037 | ||
| Rad52 inactivation is synthetically lethal with BRCA2 deficiency | Q28300346 | ||
| Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation | Q28303219 | ||
| DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer | Q28477059 | ||
| APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival | Q28484500 | ||
| ATM and related protein kinases: safeguarding genome integrity | Q29547735 | ||
| Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM | Q29614843 | ||
| Single-strand break repair and genetic disease | Q29615347 | ||
| DNA repair pathways as targets for cancer therapy | Q29615572 | ||
| Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data | Q30573716 | ||
| RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning | Q30992648 | ||
| Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas | Q33272795 | ||
| DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis | Q38852980 | ||
| The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions | Q38903633 | ||
| DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity | Q38908391 | ||
| Global estimates of cancer prevalence for 27 sites in the adult population in 2008. | Q38920305 | ||
| An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression | Q39222368 | ||
| Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells | Q39270354 | ||
| Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. | Q39364366 | ||
| Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays | Q39567497 | ||
| Carbon-Ion Radiation Therapy for Pelvic Recurrence of Rectal Cancer | Q39634769 | ||
| Radiation induced DNA DSBs: Contribution from stalled replication forks? | Q39679676 | ||
| Carbon-ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma | Q39690590 | ||
| Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration | Q39958626 | ||
| The Ku-dependent non-homologous end-joining but not other repair pathway is inhibited by high linear energy transfer ionizing radiation | Q40004856 | ||
| Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin | Q40212276 | ||
| PARP is important for genomic stability but dispensable in apoptosis | Q40442742 | ||
| The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors. | Q40480069 | ||
| BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance | Q40771883 | ||
| DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity | Q40959500 | ||
| Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function | Q41539026 | ||
| PARP inhibitors: the race is on. | Q42356655 | ||
| Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening | Q42763386 | ||
| Homologous recombination contributes to the repair of DNA double-strand breaks induced by high-energy iron ions | Q43205000 | ||
| DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway | Q44587676 | ||
| Recent insights into the biological action of heavy-ion radiation. | Q46328892 | ||
| AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies | Q46368427 | ||
| DNA repair, genome stability and cancer: a historical perspective | Q47883620 | ||
| The centenary of the discovery of the Bragg peak. | Q48640846 | ||
| Partial breast irradiation delivered with proton beam: results of a phase II trial. | Q51166688 | ||
| Track structure in radiation biology: theory and applications. | Q52243442 | ||
| The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. | Q54779449 | ||
| Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1971-1991) | Q74780063 | ||
| RBE, reference RBE and clinical RBE: applications of these concepts in hadron therapy | Q77963008 | ||
| Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week | Q81382191 | ||
| Evolving drug targets in DNA base excision repair for cancer therapy | Q82704969 | ||
| Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk | Q83498129 | ||
| Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis | Q84480800 | ||
| Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer | Q84491970 | ||
| Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base | Q33273283 | ||
| Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials | Q33273592 | ||
| Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. | Q33273771 | ||
| Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation | Q33369693 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| Hydroxyl radicals and DNA base damage | Q33538095 | ||
| Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells | Q33588354 | ||
| The many functions of APE1/Ref-1: not only a DNA repair enzyme | Q33609187 | ||
| RAD51 interconnects between DNA replication, DNA repair and immunity. | Q33636125 | ||
| Redox regulation of DNA repair: implications for human health and cancer therapeutic development | Q33830130 | ||
| Assessing the risk of second malignancies after modern radiotherapy | Q33914324 | ||
| Targeting DNA repair pathways for cancer treatment: what's new? | Q34015040 | ||
| Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding | Q34025945 | ||
| A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe | Q34089160 | ||
| Targeting DNA repair proteins for cancer treatment | Q34208979 | ||
| RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells | Q34273832 | ||
| Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement | Q34306334 | ||
| An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. | Q34316998 | ||
| Mechanisms of double-strand break repair in somatic mammalian cells | Q34317108 | ||
| Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors | Q34334481 | ||
| Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes | Q34389948 | ||
| A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex | Q34728646 | ||
| Repair of HZE-particle-induced DNA double-strand breaks in normal human fibroblasts | Q34764425 | ||
| DNA-PKcs inhibition sensitizes cancer cells to carbon-ion irradiation via telomere capping disruption | Q34980859 | ||
| Unrepaired clustered DNA lesions induce chromosome breakage in human cells | Q35002550 | ||
| Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth | Q35206699 | ||
| Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer | Q35216218 | ||
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 | ||
| The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Radiotherapy for Cancer including a Prospective Survey of Radiotherapy Practice in Sweden 2001--Summary and Conclusions | Q35574838 | ||
| The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature | Q35584522 | ||
| CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. | Q35640007 | ||
| The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses | Q35763894 | ||
| Mechanism of cluster DNA damage repair in response to high-atomic number and energy particles radiation | Q35868826 | ||
| Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer | Q35901185 | ||
| The life and death of DNA-PK. | Q35980970 | ||
| Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy | Q36097431 | ||
| A review of update clinical results of carbon ion radiotherapy | Q36119520 | ||
| DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion | Q36187532 | ||
| The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines | Q36218369 | ||
| O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas | Q36288503 | ||
| Fanconi anaemia genes and susceptibility to cancer | Q36602573 | ||
| DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking | Q36637260 | ||
| Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells | Q36654891 | ||
| Nonenzymatic role for WRN in preserving nascent DNA strands after replication stress. | Q36664165 | ||
| Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair | Q36684843 | ||
| A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia | Q36685934 | ||
| Replication stress induced site-specific phosphorylation targets WRN to the ubiquitin-proteasome pathway | Q36729343 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| The Emerging Role of Carbon-Ion Radiotherapy | Q36973646 | ||
| G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer | Q37071564 | ||
| Mutual regulation between DNA-PKcs and Snail1 leads to increased genomic instability and aggressive tumor characteristics. | Q37073635 | ||
| DNA double strand break repair via non-homologous end-joining | Q37135926 | ||
| BRCA1 and BRCA2: different roles in a common pathway of genome protection | Q37149848 | ||
| Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype | Q37162103 | ||
| Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance | Q37172320 | ||
| Analysis of the activities of RAD54, a SWI2/SNF2 protein, using a specific small-molecule inhibitor | Q37272096 | ||
| Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. | Q37322905 | ||
| Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. | Q37330762 | ||
| DNA repair in mammalian cells: Base excision repair: the long and short of it. | Q37372532 | ||
| DNA repair in mammalian cells: Direct DNA damage reversal: elegant solutions for nasty problems | Q37372535 | ||
| Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation | Q37372941 | ||
| STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. | Q37502349 | ||
| Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. | Q37670414 | ||
| Homologous recombination in cancer development, treatment and development of drug resistance. | Q37721025 | ||
| Bringing the heavy: carbon ion therapy in the radiobiological and clinical context | Q37727823 | ||
| Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. | Q37785349 | ||
| P433 | issue | Suppl 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Radiotherapy | Q58698579 |
| P304 | page(s) | S822-S839 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Translational cancer research | Q27724317 |
| P1476 | title | Repurposing DNA repair factors to eradicate tumor cells upon radiotherapy | |
| P478 | volume | 6 |
Search more.